NCT04005287View on ClinicalTrials.gov

A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

December 15, 2021

Study Completion Date

December 15, 2021

Conditions

Peripheral NeuropathyPainful Diabetic NeuropathyDiabetic Neuropathies, Painful

Interventions

DRUG

WST-057 (4% pirenzepine) Lose Dose 2mL

Topical Solution

DRUG

WST-057 (4% pirenzepine) High Dose 4mL

Topical Solution

DRUG

Placebo Low Dose

Topical Solution

DRUG

Placebo High Dose

Topical Solution

Trial Locations (5)

T6G 2E1

University of Alberta, Edmonton

L8N 3Z5

McMaster University Medical Centre, Hamilton

K1Y 4E9

Ottawa Hospital Research Institute Civic Campus, Ottawa

M5G 2C4

Toronto General Hospital, Toronto

J1H 5N4

CRCHUS, Sherbrooke

All Listed Sponsors

lead

WinSanTor, Inc

INDUSTRY

NCT04005287 - A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy | Biotech Hunter | Biotech Hunter